| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.66% | 88.30% | 93.95% | 90.48% | 88.19% | 100.00% | — | — | — | — | — | — |
| Operating Margin | 20.01% | 12.74% | 8.83% | -6924.20% | -5154.28% | -179996.05% | -111220.39% | -114736.84% | -78099.84% | -51953.37% | — | — |
| EBITDA Margin | 20.02% | 12.76% | 8.92% | -6913.32% | -5150.07% | -179892.11% | -111154.61% | -114678.95% | -78045.66% | -51911.95% | — | — |
| Net Margin | 72.56% | 7.11% | 5.42% | -7121.54% | -5204.08% | -183803.29% | -113730.92% | -114132.89% | -77944.74% | -51482.17% | — | — |
| Current Ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 | 8.25 | 16.64 |
| Quick Ratio | 3.29 | 5.03 | 5.18 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 | 8.25 | 16.64 |
| Debt / Equity | 0.38 | 1.10 | 0.62 | 1.21 | 0.29 | 0.06 | 0.75 | 0.00 | — | — | — | — |
| ROE | 69.01% | 10.52% | 7.90% | -338.53% | -146.78% | -53.79% | -447.68% | -721.76% | -176.85% | -218.17% | -61.97% | -69.64% |
| ROA | 42.06% | 4.05% | 3.84% | -102.46% | -91.70% | -44.66% | -106.05% | -207.47% | -121.66% | -142.85% | -55.47% | -64.30% |
| Asset Turnover | 0.58 | 0.57 | 0.71 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
| Book Value / Share | 4.01 | 1.39 | 1.08 | 0.43 | 1.79 | 4.50 | 0.44 | 0.32 | 1.08 | 0.73 | — | — |
TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing novel therapies for B‑cell mediated diseases. The company’s primary commercial product is BRIUMVI, an anti‑CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis, addressing clinically isolated syndrome, relapsing‑remitting disease, and active secondary progressive disease. TG Therapeutics also maintains a pipeline targeting B‑cell malignancies and autoimmune disorders, including candidates such as TG‑1701, an oral covalent Bruton’s tyrosine kinase (BTK) inhibitor, Azer‑Cel, an allogeneic CD19 CAR T therapy, and TG‑1801, an anti‑CD47/CD19 bispecific antibody, primarily in early-stage clinical development. The company generates most of its revenue from BRIUMVI sales in the United States, with additional contributions from international markets. TG Therapeutics, Inc., founded in 1993 and headquartered in Morrisville, North Carolina, operates within the health sector as a specialized player in immunology and oncology, aiming to provide targeted treatments for complex B‑cell driven conditions.